证券代码：605388 证券简称：均瑶健康 公告编号：2025-035 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 湖北均瑶大健康饮品股份有限公司 2024年年度权益分派实施公告 A 股每股现金红利0.08元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/19 | － | 2025/6/20 | 2025/6/20 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 23 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 差异化分红送转方案： （1）截至本公告披露日，公司总股本 600,484,000 股，扣除回购专户的股份数 14,660,0 ...

Core Viewpoint - The article discusses the recent positive developments in the China-US trade negotiations, highlighting the agreement framework reached between the two countries, which aims to resolve trade tensions and address export restrictions on rare earth minerals and magnets [1]. Group 1: Trade Negotiations - Chinese and US teams have reached a preliminary agreement framework after two days of negotiations, which is expected to be approved by President Trump soon [1]. - The framework adds substantial content to the previously stalled agreement on reducing retaliatory tariffs due to China's export restrictions on key minerals [1]. - The negotiations are characterized as candid, in-depth, and constructive, with both sides exchanging views on trade issues of mutual concern [1][2]. Group 2: Market Reactions - Following the positive news from the trade talks, the A-share market rebounded, with the Shanghai Composite Index rising by 0.52% to surpass 3400 points, despite a decrease in trading volume [2][4]. - The rare earth permanent magnet sector saw significant gains, with several stocks hitting the daily limit up, indicating strong market sentiment [5]. Group 3: Industry Developments - Jinli Permanent Magnet announced it has obtained export licenses for the US, Europe, and Southeast Asia, reflecting the potential for increased international trade in the sector [3]. - The automotive parts sector also experienced notable gains, with several companies committing to shorten payment terms to suppliers, indicating a shift in industry dynamics [6]. Group 4: Financial Insights - The article provides insights into the performance of various indices, noting that over 1700 index funds exist, with the highest dividend yield index being the Hong Kong Stock Connect Mainland Financial Index at 9.37% [7][8]. - A total of 48 indices were identified that meet the criteria of having a fund size of at least 2 billion and a dividend yield above 3%, with 16 indices yielding over 6% [9]. Group 5: Capital Flow - The net inflow of capital into the market was reported at 253.86 billion, with the non-bank financial sector seeing the largest inflow [15]. - Specific stocks such as Jianghuai Automobile and Ningde Times attracted significant attention from investors, indicating strong market interest in these companies [15][18].

证券代码：605388 证券简称：均瑶健康 公告编号：2025-034 湖北均瑶大健康饮品股份有限公司 关于召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 6 月 17 日（星期二）上午 10:00-11:00 会议召开方式：网络文字互动 投资者可于 6 月 16 日（星期一）16:00 前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱 juneyaodairy@juneyao.com 进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）已于 2025 年 4 月 30 日发布《公司 2025 年第一季度报告》，为便于广大投资者更全面深入地了解 公司 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 6 月 17 日上午 10:00-11:00 举行 2025 年第一季度业绩说明会，就投资者关心的问题进行交流， 在信息披露允许的范围内就投资者普遍关注 ...

Core Viewpoint - Junyao Health, known as the "first stock of lactic acid bacteria drinks," received a warning letter for failing to timely disclose its performance loss announcement, marking its first loss since going public in 2020 [2][5][10]. Financial Performance - In 2024, Junyao Health reported revenue of 1.458 billion yuan, a year-on-year decline of 10.77%, and a net profit loss of 29.12 million yuan, a year-on-year drop of 150.57% [7][10]. - The loss was primarily attributed to impairment provisions for goodwill (36.43 million yuan), inventory write-downs (12.76 million yuan), and credit impairment losses (36.60 million yuan) [8]. Stock Market Reaction - Despite the poor financial performance, Junyao Health's stock price surged, closing at 12.05 yuan per share on the first trading day after receiving the warning letter, marking a 10.05% increase and a new high for the year [2][13]. - Analysts suggest that the regulatory penalty has removed uncertainty, contributing to the stock's recovery, although there may be emotional or artificial factors influencing the price movements [6][13]. Executive Actions - During the stock price surge, several executives, including directors and supervisors, engaged in concentrated share sell-offs, totaling 383,400 shares and approximately 3.5373 million yuan in cash [4][15]. - The shareholding structure shows significant pledging, with the largest shareholder, Junyao Group, pledging about 151 million shares, accounting for 76.69% of its holdings and 25.11% of the total share capital [19][20].

证券代码：605388 证券简称：均瑶健康 公告编号：2025-034 湖北均瑶大健康饮品股份有限公司 关于召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 6 月 17 日（星期二）上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 会议召开方式：网络文字互动 投资者可于 6 月 16 日（星期一）16:00 前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱 juneyaodairy@juneyao.com 进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）已于 2025 年 4 月 30 日发布《公司 2025 年第一季度报告》，为便于广大投资者更全面深入地了解 公司 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 ...

极目新闻记者 柴荆 因存在未按规定披露2024年度业绩预告违规事实，近日，湖北证监局对湖北均瑶大健康饮品股份有限公司(以下简称均瑶健康或公司)、王均豪、俞巍、崔 鹏、郭沁采取出具警示函措施。 公司上述行为违反了《上市公司信息披露管理办法》(证监会令第182号)第三条第一款、第十七条的规定。王均豪作为公司董事长、俞巍作为总经理、崔鹏 作为财务总监、郭沁作为董事会秘书，未按照《上市公司信息披露管理办法》(证监会令第182号)第四条、第五十一条第二款和第三款的规定履行勤勉尽责 义务,对公司上述违规行为负有主要责任。 根据《上市公司信息披露管理办法》(证监会令第182号)第五十二条的规定，湖北证监局决定对湖北均瑶大健康饮品股份有限公司、王均豪、俞巍、崔鹏、 郭沁采取出具警示函的行政监管措施，并记入证券期货市场诚信档案。 均瑶健康对此公告称，公司及相关责任人将加强证券法律法规学习，提高规范意识，避免类似问题再次发生。本次行政监管措施不会影响公司正常的生产经 营活动。 均瑶健康属于食品饮料行业，主营业务涉及含乳饮料中的常温乳酸菌系列饮品的研发、生产和销售。公司于2020年8月18日上市，成为国内"常温乳酸菌第一 股"。2 ...

湖北均瑶大健康饮品股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任 重要内容提示： 证券代码：605388 证券简称：均瑶健康 公告编号：2025-033 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）股票于 2025 年 6 月 5 日、6 月 6 日、6 月 9 日连续 3 个交易日内收盘价格涨幅偏离值累计超过 20%。根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情 形。 经公司自查及向公司控股股东、实际控制人发函核实、确认，截至本公 告披露日，除公司已披露事项外，不存在其它应披露而未披露的重大事项。 请广大投资者理性投资，注意股票二级市场的交易风险。 一、股票交易异常波动的具体情况 公司股票于 2025 年 6 月 5 日、6 月 6 日、6 月 9 日连续 3 个交易日内收盘 价格涨幅偏离值累计超过 20%。根据《上海证券交易所交易规则》的有关规定， 属于股票交易异常波动情形。 二、公司关注并核实的相关情况 （一）生产经营情况 1 经公司自查，公司目前生产经营活动正 ...

Investment Rating - The report maintains a "Recommendation" rating for the food and beverage industry, indicating that the industry index is expected to outperform the benchmark index by more than 10% [5]. Core Insights - The food and beverage sector in A-shares has seen a decline of 2.12% over the past two weeks, underperforming the Shanghai Composite Index by 3.22 percentage points [2][14]. - Within the sector, soft drinks (+9.45%), snacks (+5.48%), and other alcoholic beverages (+4.98%) have shown the highest gains, while dairy products (-3.81%), liquor (-3.64%), and fermented seasoning products (-1.26%) have experienced the largest declines [2][14]. - Notable individual stock performances include Junyao Health (+72.44%), Hainan Coconut Island (+20.26%), and Miaokelando (+19.95%) leading in gains, while Wufangzhai (-10.35%), ST Jiajia (-6.92%), and Shanxi Fenjiu (-5.41%) faced the largest losses [2][14]. Summary by Sections Market Review - The food and beverage industry in A-shares has underperformed compared to major indices, with a year-to-date decline of 2.57% [14]. - The report highlights the performance of various sub-sectors, with soft drinks and snacks showing resilience while liquor and dairy face challenges [2][14]. Key Data Tracking - The report provides pricing data for key products, such as the price of Feitian Moutai at 2,130 RMB for original boxes and 2,050 RMB for bulk, reflecting a decrease of 25 RMB and 50 RMB respectively over two weeks [3][29]. - The average price of fresh milk in major production areas is reported at 3.06 RMB per kilogram, down 8.4% year-on-year [36]. Key Events Tracking - The report notes that the food manufacturing sector's profit increased by 1.1% year-on-year in the first four months of 2025, with total revenue reaching 713.58 billion RMB [4][55]. - Performance in the e-commerce space during the Tmall 618 event shows strong sales for brands like Three Squirrels and Good Products Store [4][55]. Investment Recommendations - For the liquor segment, the report suggests focusing on high-end brands with strong market positions, such as Guizhou Moutai and Wuliangye, while also considering regional leaders with favorable competitive dynamics [10][56]. - In the broader consumer goods category, the report highlights the rising popularity of yellow wine and the seasonal uptick in beer consumption, alongside strong performance in snack foods and energy drinks [10][56].

智通财经6月9日电，均瑶健康(605388.SH)发布异动公告，公司于2025年2月28日披露了《湖北均瑶大健 康饮品股份有限公司部分董监高集中竞价减持股份计划公告》。公司监事陈艳秋于本次股票交易异常波 动期间内即2025年6月6日根据减持计划减持了5700股公司股票。经公司核实，公司控股股东、实际控制 人及其一致行动人，以及公司其他董事、监事、高级管理人员在公司本次股票交易异常波动期间不存在 买卖公司股票的情况。 均瑶健康：监事陈艳秋于6月6日根据减持计划减持了5700股公司股票 ...

Core Viewpoint - Junyao Health, known as the "first stock of ambient lactic acid bacteria," has recently faced penalties for failing to timely announce a profit warning for its 2024 annual performance, marking its first annual loss since its listing in 2020 [1][4][5]. Financial Performance - In 2024, Junyao Health reported a revenue of 1.458 billion yuan, a year-on-year decline of 10.77% [6]. - The company recorded a net profit loss attributable to shareholders of 29.1164 million yuan for 2024, primarily due to impairment provisions totaling 3.643 million yuan for goodwill, 1.276 million yuan for inventory, and 3.660 million yuan for credit losses [4][5]. - In the first quarter of 2025, the company achieved a revenue of 401 million yuan, a year-on-year increase of 1.41%, but the net profit attributable to shareholders decreased by 58.29% to 10.91 million yuan [6]. Stock Performance - Despite the poor financial performance, Junyao Health's stock price surged over 70% in less than two weeks, from 6.35 yuan per share to 10.95 yuan per share [2][7]. Business Strategy and Challenges - The company has been diversifying into new business areas such as bottled water, probiotics, and supply chain management, but these efforts have not yet yielded significant results [9][11]. - The probiotics segment, which is a key focus for the company, has faced challenges including low industry entry barriers, intense price competition, and changing consumer preferences towards low-sugar products [10]. - The supply chain business, acquired in 2022, failed to meet its revenue and profit commitments, contributing to the company's financial difficulties [11].